Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
Do you think it's appropriate to run separate NGS panels on biopsies from lesions in both the right and left lung in a patient suspected of two lung primaries?
Related Questions
How often, if ever, do patients with initially negative targetable mutation workup become positive later in recurrent lung cancer?
What is your preferred first line approach to patients with Stage IV non-squamous NSCLC with good performance status, no driver mutations, PD-L1 low-positive, and CKD IIIB or worse, CrCl < 45 mL/min?
What is your approach for an RA patient with lung cancer who is starting immunotherapy?
What is your preferred approach for managing oligoprogressive NSCLC during second-line or later systemic therapy if patient is otherwise responding well at other sites of disease?
Is there a role for surgical debulking for patients with stage IV lung sarcomatoid carcinoma?
What adjuvant therapy, if any, would you offer for a young fit patient with stage IB lung adenocarcinoma harboring an EGFR A763_Y764insFQEA who received no prior therapy?
How would you approach a patient with limited stage SCLC who progressed immediately after completing chemoradiation with brain metastasis?
Would you offer adjuvant osimertinib in a patient with complete pathologic response to neoadjuvant platinum doublet for a stage IIIA resected EGFR mutant lung adenocarcinoma?
In cases where EGFR NSCLC has transformed into small-cell lung cancer after treatment with Osimertinib, and with no CNS involvement, is it advisable to continue osimertinib alongside chemotherapy?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?